Statistical Analysis The study initially had a power greater than 80 percent to detect differences in both primary and secondary outcomes in 250 patients, with a two-sided alpha of 0.05, on the basis of a 2.5-point difference in the RDQ and a 1.0-point difference about the pain rating. After early difficulty in recruitment and a well planned interim evaluation of the first 90 patients, the target was reduced by us sample size to 130 patients, with approval from the independent basic safety and data monitoring plank. The decision to change the mark enrollment was powered by accrual rates and revised power calculations primarily.0-point difference between groups about the RDQ and a 1.5-point difference in the pain rating versions with adjustment for baseline values of the results measure, recruitment site, and an indicator of study group as the predictor of interest.AEZS-130 ) – June 21, 2010: Display at the 92nd Annual Endocrine Culture Achieving and Expo of positive data on AEZS-130, a ghrelin mimetic for therapeutic and diagnostic use. AEZS-131 and 132 – April 20, 2010: Presentations at AACR’s annual conference in Washington, D.C., of preclinical data on Erk inhibitor, AEZS-131, and on Erk/PI3K dual inhibitor, AEZS-132. April 20 Corporate developments -, 2010: Completion of a $15.0 million registered direct offering with certain institutional traders. – April 23, 2010: Regained compliance with Nasdaq’s minimum bid price listing requirement. – June 21, 2010: Completion of a $12.1 million registered direct offering with certain institutional traders. Subsequent to Quarter-End – July 8, 2010: Display at the 7th International Congress of Neuroendocrinology in Rouen, France, of a scientific poster entitled, Use of the Orally Dynamic Ghrelin Mimetic AEZS-130 as a Simple Test for the Medical diagnosis of Growth Hormone Deficiency in adults .